$QXL

Quantum X Labs Inc.: Former Mossad Chief, Yossi Cohen, Strategic Advisor to SoftBank, Joins Quantum X Labs as President of Scientific Advisory Board

Quantum X Labs (QXL) appointed Yossi Cohen, former Mossad chief and SoftBank advisor, as President of its Scientific Advisory Board. Cohen will guide QXL's quantum tech roadmap, focusing on defense, aerospace, and cybersecurity. QXL develops quantum computing, error correction, and sensing tech. Cohen's role aims to bridge QXL's science with real-world strategic, commercial, and security needs.

Original reporting
Published Sep 15, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 12:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$QXL
Bullish
medium confidence
Mentioned
$QXL
Relevance
5/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$QXLBullishLow
01

Why it matters

The addition of a former intelligence chief could accelerate government contracts and partnerships, but the immediate financial impact is uncertain.

02

Market read

Exec hire news with modest relevance; may benefit long-term strategic positioning.

03

What to watch

Potential regulatory scrutiny of quantum tech in defense applications.

Relevance 5/10Novelty 6/10Timing: Sept 15 2026

Background

Quantum X Labs focuses on quantum computing, sensing, and cybersecurity, seeking to commercialize technologies for critical infrastructure.

Company-level read

Ticker impact

$QXLBullishMedium confidence
Context

Quantum X Labs announced the appointment of former Mossad chief Yossi Cohen as President of its Scientific Advisory Board.

Expected impact

Modest upside as market digests strategic advisory addition.

Evidence & confidence

Executive appointments typically have limited immediate price effect, but Cohen's stature could attract strategic partnerships.

Market effects

Highlights growing interest in quantum technologies for defense and aerospace sectors.

May increase visibility of Israeli quantum startups in global markets.

Limited to niche quantum and defense investors.

Counterpoint

The appointment may be symbolic with minimal operational impact.

Key entities

  • Quantum X Labs Inc.

    Nasdaq-listed quantum technology firm (QXL).

  • Yossi Cohen

    Former Director of Mossad, now strategic advisor to SoftBank.

Related articles

$QXLMed

Quantum X Hikes on News of New Director

Quantum X Labs Inc. (QXL) appointed Yossi Cohen, former Mossad director, as President of its Scientific Advisory Board. Cohen will aid in strategic direction for quantum technologies, focusing on defense and security markets. QXL shares rose 14.9% to $4.94 on the news.

$ELMed

Estee Lauder outlook revised to stable by S&P on deleveraging

S&P Global Ratings revised Estee Lauder's outlook to stable from negative, citing improved operating results and credit metrics. The agency expects adjusted leverage to fall to 1.9x by fiscal 2027, with mid-single-digit revenue growth and expanded EBITDA margins. Cash flows are projected to decline due to restructuring and investments, but the company plans to use cash balances for debt repayment.

$AZNMedAI 8/10

AstraZeneca’s Oncology Engine Faces a Key Test After Camizestrant Miss

AstraZeneca's breast cancer drug camizestrant (Etcamah) failed to meet the primary endpoint in the Phase III SERENA-4 trial, missing a key growth opportunity. The trial showed no statistically significant improvement in progression-free survival. AstraZeneca's shares fell 3% in after-hours trading. The drug remains approved for ESR1-mutated patients, with strong Phase III data supporting this indication. AstraZeneca's overall oncology portfolio and pipeline remain robust, with first-half 2026 re

$LHXHigh

L3Harris Is Down 30% and Guggenheim Calls It a Buy

L3Harris Technologies (LHX) gained 0.43% premarket after Guggenheim initiated coverage with a Buy rating and $365 price target, suggesting 49% upside. The stock is near its 52-week low, down 30% in six months. Guggenheim expects sustained growth and defense spending tailwinds. Jefferies started coverage at Hold with a $315 target, citing leadership changes and missile IPO uncertainty.